Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment | Synapse
February 11, 2026Open Access
Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment
Puntos clave
The aim is to explore the role of microRNAs as biomarkers in identifying breast cancer patients who respond differently to treatment.
Analyzed microRNA profiles in breast cancer patients
Grouped patients based on chemosensitivity to fluorouracil, adriamycin, and cyclophosphamide
Identified potential predictive biomarkers and therapeutic targets
Certain microRNAs were associated with chemoresistance or chemosensitivity
MicroRNAs may provide insight into personalized treatment strategies
Findings suggest that microRNAs could be monitored for treatment responses
Resumen
Therefore, these findings suggest that miRNAs may serve as predictive biomarkers and potential therapeutic targets in the management of breast cancer.
Me gusta
Guardar
Compartir
Ver artículo completo
Me gusta
Guardar
Compartir
Ver artículo completo
Cite This Study
Turiján-Espinoza et al. (Sun,) studied this question.